Physician profile
Sunjeev M Patel
NPI 1326040445
$1,912.28
in general payments reported to CMS, 2019-2025
19 companies · $330 in 2025
The $330 reported for 2025 was more than what 87% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $110 · 2021: $160 · 2022: $240 · 2023: $314 · 2024: $234 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $448.60 | 2019-2024 | Jornay Pm |
| Corium, LLC | $401.48 | 2022-2025 | Azstarys |
| Sobi, INC | $205.15 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $159.22 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Tris Pharma INC | $137.30 | 2020-2023 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $87.16 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $65.00 | 2019-2020 | |
| Shire North American Group INC | $56.03 | 2019 | |
| Alk-Abello, INC | $47.55 | 2025 | Neffy |
| Neos Therapeutics, Lp | $46.13 | 2019-2025 | Cotempla Xr-Odt |
| Sanofi-Aventis U.S. LLC | $45.83 | 2023-2025 | |
| Lnhc, INC | $41.11 | 2025 | Zelsuvmi |
| Rhodes Pharmaceuticals L.P. | $39.79 | 2019 | |
| Acadia Pharmaceuticals INC | $30.34 | 2023 | Daybue |
| Genentech USA, INC. | $25.81 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theracosbio, LLC | $21.72 | 2024 | Brenzavvy |
| Sanofi Pasteur INC. | $21.38 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.02 | 2020 | |
| Cipher Pharmaceuticals US LLC | $14.66 | 2025 | Natroba, Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunjeev Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.